Danocin Injectable Solution

DANOCIN Injectable Solution is a sterile, clear, fluid, pale yellow coloured solution suitable for injection, containing in each ml danofloxacin mesylate equivalent to 25 mg danofloxacin. 

Pharmacological Properties

Danofloxacin is a synthetic antibacterial with very good in vitro activity, particularly against aerobic Gram negative bacteria such as Actinobacillus pleuropneumoniae, Haemophilus somnus, Manhnheimia (Pasteurella) haemolytica and Pasteurella multocida of the Enterobacteriaceae family, which cause respiratory and digestive system diseases in cattle.
Danofloxacin exerts a bactericidal effect by inhibiting the DNA gyrase (topoisomerases) enzyme in microorganisms, thereby preventing DNA synthesis and replication, which is of vital importance in the multiplication of bacteria. It has recently been demonstrated that while DNA gyrase is the main target in Gram negative bacteria, topoisomerase IV is the target enzyme in Gram positive bacteria.
The main susceptible bacteria are; E.coli, Salmonella sp., Enterobacter sp., Serratia sp., Proteus sp., Klebsiella sp., Shigella sp., Yersinia sp., Moraxella sp., Acinobacter sp., Actinobacillus sp., Pasteurella sp., Leptospira sp., Campylobacter sp., Citrobacter sp., Haemophilus sp., Ehrlichia sp., Coxiella brunetti, Staphylococcus sp., including those resistant to methicillin and gentamicin, Neisseria gonorrhoeae, N. meningiditis, including those resistant to penicillin, Corynebacterium sp., Chlamydia sp., V.cholerae, Mycoplasma sp.’
Strep. suis, Strep. agalactia, Strep. dysgalactia, Strep. zooepidemicus, R.equi and Mycobacterium sp. show moderate susceptibility. Most anaerobic cocci, Clostridium sp., Bacteroides sp. and Ps. maltophila are generally poorly susceptible or resistant to quinolones.
After administration, DANOCIN is rapidly absorbed from the injection site and reaches high concentrations in the lung, enteric and lymphatic tissue. The concentration it reaches in the lung tissue within 1 hour is approximately 4 times the plasma concentration. The bioavailability is approximately %90. 

Indications

In cattle and calves: Used in respiratory and digestive system infections caused by microorganisms susceptible to danofloxacin  (Mannheimia haemolytica, Pasteurella multocida, Haemophilus somnus) and in calf septicaemias (Escherichia coli). 

Dosage & Administration

‘Unless otherwise recommended by the veterinarian;’
It is administered subcutaneously, intramuscularly or intravenously at a dose of 1.25 mg/kg live weight/day (1 ml/20 kg body weight). Treatment with DANOCIN Injectable Solution is continued 1 time a day for 3 days. In severe cases where the desired degree of recovery cannot be achieved despite the first 3 injections, treatment may be continued for two more days. For the treatment of cattle weighing more than 450 kg, the dose should be divided so that no more than 20 ml is administered to each injection site. The recommended dose and duration should not be exceeded. Asepsis and antisepsis should be observed during use.